Ditchcarbon
  • Contact
  1. Organizations
  2. Astellas US Holding, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

Astellas US Holding, Inc. Sustainability Profile

Company website

Astellas US Holding, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 2005, Astellas has rapidly evolved, focusing on innovative solutions in areas such as oncology, urology, and immunology. The company is renowned for its commitment to research and development, which has led to the creation of unique therapies that address unmet medical needs. With a strong market position, Astellas has achieved significant milestones, including the successful launch of several key products that enhance patient outcomes. The company’s dedication to advancing healthcare through cutting-edge science and patient-centric approaches sets it apart in a competitive landscape. Astellas continues to strive for excellence, making a meaningful impact on global health.

DitchCarbon Score

How does Astellas US Holding, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

66

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Astellas US Holding, Inc.'s score of 66 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.

78%

Let us know if this data was useful to you

Astellas US Holding, Inc.'s reported carbon emissions

Inherited from Astellas Pharma Inc.

Astellas US Holding, Inc. currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family that includes Astellas Pharma Inc., which may influence its climate commitments and initiatives. Astellas Pharma Inc. has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives are cascaded to Astellas US Holding, Inc. as a current subsidiary, indicating a commitment to reducing carbon emissions in alignment with industry standards. While specific reduction targets or achievements for Astellas US Holding, Inc. are not detailed, the overarching goals from Astellas Pharma Inc. suggest a proactive approach to addressing climate change. The company is expected to align its strategies with these broader commitments, focusing on sustainability and emissions reduction in its operations.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2005201020112012201320142015201620172018201920202021202220232024
Scope 1
108,000,000
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
-
-
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
-
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Astellas US Holding, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Astellas US Holding, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Astellas US Holding, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Astellas US Holding, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Astellas US Holding, Inc.'s Scope 3 Categories Breakdown

Astellas US Holding, Inc.'s Scope 3 emissions, which increased by 14% last year and decreased by approximately 7% since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 85% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
85%
Capital Goods
7%
Business Travel
3%
Fuel and Energy Related Activities
2%
Upstream Transportation & Distribution
2%
Downstream Transportation & Distribution
1%
Downstream Leased Assets
<1%
Employee Commuting
<1%
Waste Generated in Operations
<1%
End-of-Life Treatment of Sold Products
<1%

Astellas US Holding, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Astellas US Holding, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Astellas US Holding, Inc.'s Emissions with Industry Peers

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Let us know if this data was useful to you

Usage Policy

You're welcome to quote or reference data from this page, but please include a visible link back to this URL.

Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.

See our License Agreement for more details.

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251211.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
Use CaseSBTi-aligned baselining & progress trackingSupplier EngagementClimate-informed sourcing strategyEmission ReportingSustainable Finance
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelogWhitepaper
AboutTeamCareersLicense AgreementPrivacy